SCHEMBL6820043

SCHEMBL6820043

CC1CC(=O)C=C2CCc3ccccc3N21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 6/20 0.67
NOTUM Q6P988 3/20 0.42
HSD17B3 P37058 1/20 0.40
ALDH1A1 P00352 1/20 0.39
OPRM1 P35372 4/20 0.38
OPRK1 P41145 3/20 0.38
OPRL1 P41146 3/20 0.38
ROCK1 Q13464 1/20 0.38
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD1 P21728 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
ADRA1A P35348 1/20 0.37
DRD3 P35462 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823141 0.80 SRD5A1 (1.00) SRD5A1NOTUMHSD17B3ROCK1
SCHEMBL6819941 0.76 SRD5A1 (0.46) SRD5A1NOTUMOPRM1OPRK1OPRL1
SCHEMBL6823140 0.76 NOTUM (0.45) SRD5A1NOTUMALDH1A1ROCK1
SCHEMBL6819871 0.72 SRD5A1 (0.55) SRD5A1NOTUMALDH1A1OPRM1OPRK1
SCHEMBL6942297 0.69 SRD5A1 (0.39) SRD5A1NOTUMALDH1A1OPRM1OPRK1
SCHEMBL22005465 0.68 ROCK1 (0.51) NOTUMALDH1A1ROCK1
SCHEMBL7075121 0.68 ROCK1 (0.51) NOTUMALDH1A1ROCK1
SCHEMBL6820047 0.68 SRD5A1 (1.00) SRD5A1HSD17B3ALDH1A1ROCK1
SCHEMBL17655192 0.67 SLC6A2 (0.41) SRD5A1NOTUMHSD17B3ALDH1A1OPRM1
SCHEMBL6815740 0.67 AADAT (0.38) SRD5A1NOTUMALDH1A1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1102765-B1 PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C]QUINOLIZIN-3-ONES DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2003-09-17 EP claimed
EP-0999747-B1 USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS APPLIED RESEARCH SYSTEMS (AN) 2003-04-23 EP claimed
US-6514912-B1 Use of benzo[C]quinolizine derivatives as plant growth regulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-02-04 US claimed
EP-0999747-A1 USE OF BENZO C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS Applied Research Systems ARS Holding N.V. (AN) 2000-05-17 EP claimed
WO-1999005913-A1 USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 1999-02-11 WO claimed
US-6723850-B1 N-ALKYLATION OF THE THIOAMIDE WITH A VINYL KETONE IN PRESENCE OF A STRONG BASE; 6-CHLORO-(1H)-3,4-DIHYDROQUINOLIN-2-THIONE REACTED WITH ETHYL VINYL KETONE APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-04-20 US disclosed
EP-1102765-B1 PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C]QUINOLIZIN-3-ONES DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2003-09-17 EP disclosed
US-6555549-B2 Useful in treating acne, baldness, prostatic cancer and hypertrophy in men and hirsutism in women APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2003-04-29 US disclosed
EP-0999747-B1 USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS APPLIED RESEARCH SYSTEMS (AN) 2003-04-23 EP disclosed
US-6552034-B2 Cyclization of a silylated butadiene reacted with a 2-oxo-1,2,3,4-tetrahydroquinoline; acne; alopecia; prostatic cancer and hypertrophy; hirsutism in women; skin and glandular disorders; anticarcinogenic agents APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2003-04-22 US disclosed
EP-0880520-B1 BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS APPLIED RESEARCH SYSTEMS (AN) 2003-04-16 EP disclosed
US-6514912-B1 Use of benzo[C]quinolizine derivatives as plant growth regulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-02-04 US disclosed
US-20010047098-A1 Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors MERCK SERONO SA (CH) 2001-11-29 US disclosed
US-20010044542-A1 Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors MERCK SERONO SA (CH) 2001-11-22 US disclosed
US-6303622-B1 FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2001-10-16 US disclosed
EP-0999747-A1 USE OF BENZO C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS Applied Research Systems ARS Holding N.V. (AN) 2000-05-17 EP disclosed
WO-1999005913-A1 USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044542-A1 Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors CYP3A5, CYP51A1, CYP2F1 SRD5A1 8/4885NOTUM 551/4885HSD17B3 91/4885
US-20010047098-A1 Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors CYP3A5, CYP51A1, CYP2F1 SRD5A1 8/4885NOTUM 551/4885HSD17B3 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.